Source | Cyber blue
Edit | color
countdown! With only the last 2 months left, the provinces will digest nearly a thousand medicines
01
Nearly a thousand medicines will no longer be reimbursed in multiple provinces
Today (October 22), the shaanxi provincial medical insurance bureau's publicity period for the second batch of digestion lists of the original provincial supplementary drugs is coming to an end.
According to the document arrangement, a total of 86 drugs were transferred this time, including 43 Western medicines and 43 proprietary Chinese medicines. The drugs transferred out include large varieties such as YanHu Ning, Cefmeme, Compound Sanqi Capsules, Pudi Blue Anti-inflammatory Oral Liquid and so on.
October has entered the end, according to the requirements of the National Medical Insurance Bureau, local medical insurance supplementary drugs should complete the three batches of withdrawal work by the end of June 2022, and the key monitoring catalogue drugs will take the lead in moving out of the medical insurance catalogue. In principle, local supplementary varieties should be cleaned up within three years, and the proportion of three-year cleaned varieties was 40%, 40% and 20% respectively.
According to the notice of the provinces, it can be found that January 2022 is also the time for the provinces to intensively transfer drugs from the medical insurance list. With nearly 2 months left, thousands of medicines will no longer be reimbursed.
Beijing(182)
Recently, the Beijing Municipal Medical Insurance Bureau issued the "Notice on Announcing the Second Batch of Drug Varieties and Standardized Drug Names of Non-National Medical Insurance Drug Catalogs in the City".
The notice shows that from December 1, 2021, 182 non-national medical insurance drug catalogue varieties such as "atropine promethazine injection" will be deleted from the city's medical insurance drug catalog, and the names and dosage forms of 48 drugs such as "Qingkailing injection" will be standardized and adjusted.
Guizhou(339)
On August 3, the Guizhou Medical Insurance Bureau and the Guizhou Human Resources and Social Security Department issued the "Notice on Transferring Some Drugs out of the Catalogue of Drugs for Work Injury Insurance and Maternity Insurance in Guizhou Province (2021)", saying that from January 1, 2022, 339 drugs such as sidi iodine will be transferred out of the Drug Catalogue. Before the above-mentioned drugs are transferred, they shall continue to be paid in accordance with the relevant provisions of the Drug List.
Qinghai(129)
Previously, the Qinghai Provincial Medical Insurance Bureau issued the Notice on Printing and Distributing the Supplementary Drug Digestion Catalogue of Qinghai Province. The notice shows that in 2020, a total of 129 varieties of drugs that were not recruited and used by the national key monitoring drugs and the drug procurement platform of Qinghai Province in the previous year were transferred, and medical insurance and work injury insurance reports were stopped from January 1, 2021.
Zhejiang(118)
On August 3, the Zhejiang Medical Insurance Bureau and the Zhejiang Department of Human Resources and Social Security issued the "Notice on Transferring Some Drugs out of the Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in Zhejiang Province", which requires that from January 1, 2022, 118 drugs such as amoxicillin dicloxacillin be transferred out of the Zhejiang Provincial Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue.
Sichuan(145)
On July 26, the Sichuan Medical Insurance Bureau issued the "Notice on Further Improving the Digestion of Class B Drugs in the Province's Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (Draft for Comment)" that after expert argumentation, the Sichuan Provincial Medical Insurance Bureau decided to transfer 145 drugs such as butyl boron ointment out of the payment scope of Sichuan Province's basic medical insurance, work injury insurance and maternity insurance from January 1, 2022.
Jiangsu(156)
On July 14, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice of the Department of Human Resources and Social Security of Jiangsu Province on Publishing the Second Batch of Supplementary Drugs in the Catalogue of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance", showing:
Provincial medical insurance agencies should promptly do a good job in maintaining the information of the basic medical insurance, work injury insurance and maternity insurance drug catalog database in Jiangsu Province, and transfer out all varieties under the generic name of the second batch of digestion drugs involved. At the same time, all drugs that were originally maintained under the generic name of the drug and did not comply with the current generic name rules were transferred out synchronously.
At the same time, Jiangsu Province announced that from January 1, 2022, all the costs incurred for transferred drugs will no longer be included in the payment scope of Jiangsu Province's basic medical insurance, work injury insurance and maternity insurance funds.
Chongqing
According to the arrangement of the Chongqing Medical Insurance Bureau, Chongqing local medical insurance digests drugs in the second year and stops medical insurance reimbursement from January 1, 2022. The second year digestion medicines are as follows:
Ampicillin probenecid (oral common-release dosage form, the drug has been renamed "ampicillin probene"),flucloxacillin (injectable), cefazolin pentahydrate (injection), cefloxime (injection), ceftriaxazotazol (injection), ceftriaxonazol (injection), cefotali (injection), roxithromycin (extended-release controlled-release dosage form), persemin (injection), clozoxazone (oral regular-release dosage form), gauuroxabrin (injection), compound amino acids (8-11) (oral common-release form), deoxynucleotide (injection), Compound amino acids (15) dipeptides (2) (injectables), long-chain fatty milk (OO) (injections), BCG polysaccharides (injections), pitolimod (oral regular-release dosage forms), placental polypeptides (injections), paclitaxel liposomes (injections), recombinant modified human tumor necrosis factor (injections), vinblastamine (extended-release controlled-release dosage forms), snake enzymes (injections), gustil (injections), meclofentil (injections), acetyl gastroestrin (oral regular-release dosage forms), ambroxol (extended-release controlled-release dosage forms), Cocodeine (oral liquid), cisapride (oral regular-release dosage form), matrine (oral regular-release dosage form), ornithine aspartate (granules), ginseng glucose (injectable), coenzyme Q10 (oral regular-release dosage form), levocarnitine (oral liquid), mannan peptide (injection), fructose sodium diphosphate (oral liquid), low molecular weight dextran amino acid (injection), compound electrolyte (injection), sodium potassium magnesium calcium glucose (injection), aminoiodide (eye drops), Three-dimensional mycin (suppository), intestinal laxative capsules, QianLian tablets (granules, capsules), Monkey Earrings anti-inflammatory tablets, sub-leaf bead capsules (tablets), Shalian and stomach capsules, Mustang Chase syrup, anti-brain failure capsules, yi brain heart granules, Wuzi Yanzong oral liquid (pills, tablets, soft capsules), Schizandra syrup (capsules, tablets, granules), compound Fufang Vine Combination (capsules), compound Da Hong Pao hemostatic capsules, Hekang oral liquid (granules), hemostatic treasure granules, cardiomyoplast injection, blood house stasis soft capsules, danshen for injection, Safflower Yellow Pigment for Injection, Yixinone Tablets (Capsules), Haidan Capsules, St. John's Wort Extract Tablets, Agarwood Gas Pills (Capsules), Saw palmetite Fruit Extract Softgels, Lipid-Lowering Tongluo Softgels, Stone-Killing Choleretic Capsules, Musk Shu Huo ling, Toad Crisp Injection, Jin throat Pills, Zhenhuang Pills, Dusheng Huo Blood Tablets, Calendula Dispersible Tablets, Shu Liver And Spleen Granules, Entacapone Double Dopa Tablets (II.) (Tablets, Beijing Novartis Pharmaceutical Co., Ltd.), Pioglitazone Metformin Tablets (Tablets, Hangzhou Sino-American Huadong Pharmaceutical Co., Ltd., Jiangsu Deyuan Pharmaceutical Co., Ltd.), Ratanthimo Eye Drops (Eye Drops, Pfizer Manufacturing Belgium NV), Mixed Sugar Electrolyte Injection (Injection, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.), Peridole Indapamide Tablets (Tablets, Svea (Tianjin) Pharmaceutical Co., Ltd.), Fat Milk Amino Acids (18) Injection (Injection, Sichuan Kelun Pharmaceutical Co., Ltd.), Estradiol/Estradiol Didrogestrol Tablets Composite Packaging (Tablets, Tablets, Abbott Biologicals B.V.), Oshali Platinum Mannitol Injection (Injection, Sichuan Meida Kangjiale Pharmaceutical Co., Ltd., Chenxin Pharmaceutical Co., Ltd.), Fat-Soluble Vitamins for Injection (II.)/Water-Soluble Vitamins for Injection Package (Injection, Chengdu Tiantaishan Pharmaceutical Co., Ltd., Hebei Zhitong Biopharmaceutical Co., Ltd.), Kandi Hydrodi tablets (tablets, Jiangsu Deyuan Pharmaceutical Co., Ltd.), Compound Vitamins for Injection (3) (Injections, Liaoning Haisco Pharmaceutical Co., Ltd.), Omeprazole Sodium Bicarbonate Capsules (capsules, Xiamen Encheng Pharmaceutical Co., Ltd.), Diclofenac sodium lidocaine for injection (injection (lyophilized powder injection), Beijing Sihuan Kebao Pharmaceutical Co., Ltd.), Apricot Root Sodium Chloride Injection (Injection, Honghe Pharmaceutical (China) Co., Ltd.), Multiple Oil and Fat Emulsion Injection (C6-24) (Injection, Fresenius Kabi Austria GmbH), Compound Brain Peptide Ganglioside Injection (Injection). , Jilin Buchang Pharmaceutical Co., Ltd., the manufacturer changed its name to Jilin Tiancheng Pharmaceutical Co., Ltd.), compound astryptide injection (injection, Jilin Buchang Pharmaceutical Co., Ltd., the manufacturer changed its name to Jilin Tiancheng Pharmaceutical Co., Ltd.), Qufu Timo eye drops (eye drops, s.a. ALCON-COUVREUR n.v.), ambrobrobuterol oral solution (oral solution, Beijing Hanmei Pharmaceutical Co., Ltd.), 12 multivitamins for injection (injection, the drug has been renamed " Multivitamins for Injection (12)", Shanxi Pude Pharmaceutical Co., Ltd.), Compound Diclofenac Sodium Injection (Injection, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.), Alendronate Sodium Vitamin D3 Tablets (II.) (Tablets, Hangzhou Merck & Co., Ltd.), Clindamycin Glucose Injection (Injection), Ambroxol Hydrochloride Glucose Injection (Injection), Granisetron Hydrochloride Glucose Injection (Injection), Doxofylline Glucose Injection (Injection), Ozagire sodium glucose injection (injection), bromohexenazine hydrochloride injection (injection), clindamycin sodium chloride injection (injection), ambroxol hydrochloride sodium chloride injection (injection), famotetin sodium chloride injection (injection), todan setron hydrochloride sodium chloride injection (injection), potassium chloride chloride injection (injection), nicardipine hydrochloride sodium chloride injection (injection), Ozagrel sodium chloride injection (injection), Piracetam sodium chloride injection (injection) , ofloxacin sodium chloride injection (injection), betaxestine hydrochloride sodium chloride injection (injection), morphinonidazole sodium chloride injection (injection)
02
Medical insurance adjustment helps innovative drugs to quickly increase the volume
Industry professionals believe that in addition to accelerating the digestion of local medical insurance catalogs, the national medical insurance catalog is also dynamically adjusting, which will help the rapid release of innovative drugs.
From the perspective of the general direction of the current adjustment of the medical insurance catalogue, drugs with significant clinical value will be adjusted into the catalogue more quickly, and auxiliary drugs and drugs with poor drug economy will be gradually transferred out. In this context, the market development speed is more rapid.
Public information shows that from 2015 (pilot) to 2020, the number of innovative drugs included in the medical insurance list has been increasing. After several rounds of adjustments to the medical insurance catalogue, a large number of innovative targeted drugs have been included.
In the "Announcement on the Adjustment of the National Medical Insurance Drug Catalogue in 2021 through preliminary review of drugs and information" issued by the National Medical Insurance Bureau, the list of drugs that have obtained the next evaluation qualification series is announced, and some expensive new drugs are also listed, such as: Agironcel injection, Nosinasine sodium injection, etc.
It is worth mentioning that although innovative drugs have the opportunity to enter medical insurance, the challenges are not small. The price reduction of innovative drugs is still very large, and overall, the success rate of medical insurance negotiations in 2020 has increased from 58.82% in 2019 to 73.46%, and the average price reduction of drugs has reached 50.64%. Among them, the average price of the three PD-1 monoclonal antibodies has been reduced by nearly 70%, namely: tirelizumab, carellizumab, and trepleliumab.
After the innovative drugs are included in medical insurance, they are mostly considered to be able to achieve "price for volume". This means that the overall development of innovative drugs will be faster.
The medical insurance directory is still dynamically adjusted, with the current process of calculation, the provinces for the third year to digest 20% of the action of supplementary drugs will soon be put on the agenda, for the clinical value is not high, the efficacy is not obvious drugs, the challenge will never stop, the relevant pharmaceutical companies must be timely innovation and transformation, in order to obtain the corresponding market development opportunities.